Santen eyes uveitis market with top-line sirolimus data
This article was originally published in Scrip
Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.